GSK is paying up to $1.3 billion to license an experimental cancer drug from China’s HUTCHMED — a bet on a therapy built to attack two of cancer’s most important drivers at the same time.
The drug, HMPL-A830, is an antibody-targeted conjugate — an advanced take on antibody-drug conjugates — that acts as a dual KRAS-EGFR inhibitor: it uses an antibody to deliver a KRAS inhibitor directly to EGFR-expressing tumors while blocking both signaling pathways. The deal includes $110 million upfront and up to $1.185 billion in milestones. GSK gets global rights outside Greater China; HUTCHMED keeps China, Hong Kong, Macau and Taiwan.
Why the targets matter
KRAS mutations drive many hard-to-treat cancers, and the initial focus is on tumors with high KRAS-mutation rates: colorectal cancer (44%), lung adenocarcinoma (34%), and pancreatic cancer (up to 89%). “The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care,” said GSK oncology R&D head Dr. Hesham Abdullah.
Why it matters
RAS has been one of oncology’s hardest targets, and combining it with EGFR blockade — delivered precisely to tumors — is an ambitious approach. It’s also another example of Western pharma licensing early-stage innovation from Chinese biotech. The drug is early: a HUTCHMED-led Phase 1 trial is set to begin in the second half of 2026, so clinical proof is still ahead.